Media Centre NewsAugust 18, 2025Welcoming our new CTONewsAugust 25, 20252025 Annual ReportNewsNovember 22, 2024Genetic Signatures 2024 AGM HighlightsNewsSeptember 24, 2024A warm welcome to Allison RossiterNewsJune 4, 2024FDA Clears Genetic Signatures’ Molecular Diagnostic Solution for Gastrointestinal ParasitesNewsJune 4, 2024Genetic Signatures Appoints Former Roche Diagnostics Executive Allison Rossiter as CEONewsApril 30, 2024Genetic Signatures farewells long-standing CEO & Director, Dr. John MelkiLatest News, NewsSeptember 25, 2014Genetic Signatures EasyScreen™ Enteric Bacteria Detection Kit receives the CE-IVD MarkLatest News, NewsOctober 30, 2014Genetic Signatures expands its Board of Directors with the appointment of Pat NolandLatest News, NewsNovember 18, 2014Genetic Signatures Prepares for IPO: Prospectus now availableLatest News, NewsFebruary 6, 2015Genetic Signatures IPO now open to 20 March. Supplementary Prospectus now available. The Minimum Subscription under the Offer is fully underwritten by the Lead Manager, Lodge Corporate Pty Ltd.Latest News, NewsMarch 11, 2015Genetic Signatures achieves first sales of EasyScreen™ Respiratory Virus Detection Kit
NewsJune 4, 2024FDA Clears Genetic Signatures’ Molecular Diagnostic Solution for Gastrointestinal Parasites
NewsJune 4, 2024Genetic Signatures Appoints Former Roche Diagnostics Executive Allison Rossiter as CEO
Latest News, NewsSeptember 25, 2014Genetic Signatures EasyScreen™ Enteric Bacteria Detection Kit receives the CE-IVD Mark
Latest News, NewsOctober 30, 2014Genetic Signatures expands its Board of Directors with the appointment of Pat Noland
Latest News, NewsFebruary 6, 2015Genetic Signatures IPO now open to 20 March. Supplementary Prospectus now available. The Minimum Subscription under the Offer is fully underwritten by the Lead Manager, Lodge Corporate Pty Ltd.
Latest News, NewsMarch 11, 2015Genetic Signatures achieves first sales of EasyScreen™ Respiratory Virus Detection Kit
